Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in los angeles grades A and B

American Journal of Gastroenterology

Volumn 105, Issue 5, 2010, Pages 1046-1052

  Chen, Wei Ying ^a   Chang, Wei Lun ^a   Tsai, Yu Ching ^a   Cheng, Hsiu Chi ^a   Lu, Cheng Chan ^a   Sheu, Bor Shyang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; PANTOPRAZOLE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; TREATMENT RESPONSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS, PEPTIC; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; KAPLAN-MEIERS ESTIMATE; LOS ANGELES; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77951979062     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.632     Document Type: Article

References (25)

1. Tytgat GN. Long-term therapy for refluxive esophagitis. N Engl J Med 1995; 333: 1148-1150
2. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-657
3. Spechler SJ. Epidemiology and natural history of gastroesophageal reflux disease. Digestion 1992; 51 (Suppl 4): 3-7s.
4. Chiba N, De Gara CJ, Wilkinson JM et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810
5. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307-335
6. Dent J, Brun J, Fendrick A et al. An evidence-based appraisal of reflux disease management-the Genval workshop report. Gut 1999; 44: S1-16.
7. Lind T, Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis\a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-914
8. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of " on-demand " therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-354
9. Van Soest EM, Siersema PD, Dieleman JP et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006; 24: 377-385
10. El-Serag HB, Graham DY, Satia JA et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005; 100: 1243-1250
11. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211.
12. Murray L, Johnston B, Lane A et al. Relationship between body mass and gastro-oesophageal reflux symptoms: the Bristol Helicobacter Project. Int J Epidemiol 2003; 32: 645-650
13. Jacobson BC, Somers SC, Fuchs CS et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354: 2340-2348
14. El-Serag HB, Ergun GA, Pandolfi no J et al. Obesity increases esophageal acid exposure. Gut 2007; 56: 749-755
15. Jacobson BC, Schroy PC III. The skinny on obesity and reflux. Gastroenterology 2006; 130: 1925-1926
16. Sheu BS, Cheng HC, Chang WL et al. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol 2007; 102: 2387-2394
17. de Morais SM, Wilkinson GR, Blaisdell J et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-15422
18. Chang M, Tybring G, Dahl ML et al. Interphenotype diff erences in disposition and eff ect on gastrin levels of omeprazole: suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-518
19. Ieiri I, Kubota T, Urae A et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996; 59: 647-653
20. Furuta T, Shirai N, Takashima M et al. Eff ect of genotypic diff erences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 68: 158-168
21. Kawabata H, Habu Y, Tomioka H et al. Eff ect of diff erent proton pump inhibitors, diff erences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 17: 259-264
22. Sheu BS, Kao AW, Cheng HC et al. Esomeprazole 40 mg twice daily in triple therapy and the effi cacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005; 21: 283-288
23. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classifi cation. Gut 1999; 45: 172-180
24. Sheu BS, Chang WL, Cheng HC et al. Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole. Am J Gastroenterol 2008; 103: 2209-2214
25. Carlsson R, Dent J, Bolling-Sternevald E et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023-1029